Reuters: Regulatory News: UPDATE 1-J&J to pay $181 mln to settle improper marketing claims

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

UPDATE 1-J&J to pay $181 mln to settle improper marketing claims Aug 30th 2012, 16:31 Thu Aug 30, 2012 12:31pm EDT Aug 30 (Reuters) - Johnson & Johnson said it has agreed to pay $181 million to resolve consumer fraud claims by 36 U.S. states and the District of Columbia that it improperly marketed its Risperdal antipsychotic drug for unapproved uses. The diversified healthcare company, which has also been targeted by federal authorities for separate but related criminal allegations, said it had already set aside funds to cover the civil settlement. The funds will be divided among the states participating in the agreement, announced on Thursday. The company said the settlement was not an admission of wrongdoing.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions